Deutsche Märkte geschlossen

Armata Pharmaceuticals, Inc. (TG1N.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
2,5800+0,0400 (+1,57%)
Börsenschluss: 08:10AM CEST

Armata Pharmaceuticals, Inc.

5005 McConnell Avenue
Los Angeles, CA 90066
United States
310 665 2928
https://www.armatapharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter66

Beschreibung

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Corporate Governance

Armata Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.